Gcasa Boards Moderated - Profile

Ticker	Board	Posts	Last Post	Prem?	Lead?
No General Topic Boards are Moderated By Gcasa

Play Episode

6min

Proactive - Interviews for investors

Novo Resources targets gold at Tibooburra

Novo Resources Corp executive co-chair Mike Spreadborough and exploration manager Kas De Luca talked with Proactive about the company’s current exploration, strategy and key drilling campaigns underway in 2025. Spreadborough detailed the company's focus on standalone projects with the potential to exceed one million ounces, with current efforts centred on drilling programs at the Balla Balla project, Tibooburra Gold Project, and upcoming activity at the John Bull Project. “We’re not chasing brownfields mill feed for an existing processing plant. We’re looking for something new and exciting,” he said. De Luca shared insights into the Clone prospect at Tibooburra, highlighting its strong geological context and mineralisation indicators. “The clone thrust has been really identified and pinpointed now as a foot wall shear zone… that seems to us both in the drilling and in service to carry most of the mineralisation,” she noted. De Luca said results from surface sampling returned grades up to 89 grams per tonne, and the company has only tested a small fraction of a 60km mineralised trend. Novo expects results from three programs between now and July and continues to assess additional farm-in opportunities as part of its strategy. For more videos from Proactive, give this video a like, subscribe to our channel, and turn on notifications so you never miss an update. #GoldExploration #NovoResources #TibooburraGold #GreenfieldsExploration #JuniorMining #RCDrilling #GoldStocks #AustralianMining #MiningUpdates #ProactiveInvestors

Proactive - Interviews for investors

Pluri CEO Yaky Yanay on pioneering cell-tech solutions for global needs

Pluri Inc. (NASDAQ:PLUR) CEO Yaky Yanay joined Proactive's Stephen Gunnion with more about the company’s progress in developing and commercializing its cell-based technology platform, highlighting recent partnerships, strategic financing, and future milestones. Pluri is a biotechnology company focused on manufacturing products derived from cells—including human, animal, and plant cells—for applications across industries such as healthcare, food, and agriculture. "We are taking this tiny organism, cells... and we create products out of them," Yanay explained. A key highlight was Pluri’s collaboration with Hemafund in Ukraine to enhance the country’s preparedness for radiation emergencies. Yanay detailed the use of PLX-R18, a placenta-based therapeutic developed with US federal agencies, which has shown potential to significantly improve survival rates following radiation exposure. The discussion also covered Pluri’s recent financing activities, including a $10 million raise and the acquisition of cacao company Kokomodo. These moves are part of Pluri’s broader expansion into the food sector, addressing shortages in coffee and cacao through cell cultivation in bioreactors. Looking ahead, Yanay emphasized a strong pipeline of deals for 2025, with a focus on sustainable, cell-based solutions for some of humanity’s biggest needs. For more interviews and updates, visit Proactive’s YouTube channel. Don’t forget to like this video, subscribe, and turn on notifications for future content. #PluriInc #BiotechInnovation #CellTherapy #SustainableTech #RadiationPreparedness #CoffeeCrisis #CacaoShortage #HealthcareTech #InvestmentNews #YakyYanay #ProactiveInvestors

Proactive - Interviews for investors

Ananda Pharma adds former GW Pharmaceuticals executive as strategic advisor, advances MRX1

Ananda Pharma Plc finance director Jeremy Sturgess-Smith talked with Proactive's Stephen Gunnion about the appointment of Chris Tovey as a strategic advisor. Tovey brings significant experience from his time as chief operating officer at GW Pharmaceuticals and later Jazz Pharmaceuticals. According to Sturgess-Smith: “He’s going to bring all that experience to Ananda,” helping guide the company through its regulatory path and corporate development. Sturgess-Smith also touched on Ananda securing ethics approval to begin its first human trial of MRX1, a key milestone for the company’s therapeutic pipeline. He noted this was the first ethics approval of its kind for any Ananda trial, with recruitment expected to begin shortly in Australia. “It’s very, very exciting to have that ethics approval in the bag,” he said. Looking ahead, the company also expects ethics approvals for studies into chemotherapy-induced peripheral neuropathy and endometriosis in the next six months. For more interviews and updates, visit Proactive's YouTube channel. Don’t forget to like this video, subscribe, and hit the notification bell to stay informed.** #AnandaPharma #MRX1Trial #ClinicalTrials #CannabinoidMedicine #BiotechNews #PharmaceuticalInnovation #EthicsApproval #GWPharma #DrugDevelopment #Epidiolex #HealthInnovation #ProactiveInvestors

Proactive - Interviews for investors

Nextech3D.ai signs LOI to sell majority stake in Toggle3D.ai securing strategic non-dilutive capital

Nextech3D.ai CEO Evan Gappelberg joined Steve Darling from Proactive to announce a pivotal strategic development for the company. Nextech3D.ai has entered into a Letter of Intent to sell up to an 80% equity interest in its spin-out subsidiary, Toggle3D.ai, to TQG Technologies. The proposed transaction not only transitions Toggle3D.ai into its next phase of evolution under new majority ownership, but also provides Nextech3D.ai with a non-dilutive capital infusion of CAD $610,000, strengthening the company’s balance sheet and strategic flexibility without impacting existing shareholder equity. Gappelberg explained that the transaction will be structured in three tranche wuth TQG Technologies acquireing 11 million shares of Toggle3D.ai for CAD $610,000 in cash. Contingent on the closing of TQG’s capital raise, an additional 5 million shares will be purchased for CAD $276,000. The final stage will complete the 80% acquisition through a combination of share purchases and the vending-in of TQG’s strategic assets into Toggle3D.ai. As part of the agreement framework, a non-refundable deposit of CAD $177,000 will be paid by TQG upon the finalization of the deal’s structure by its management. Further milestone-based payments are scheduled to be completed by August 2025. Additionally, Nextech3D.ai stands to receive a performance-based bonus of CAD $710,000 if TQG successfully closes a financing round of at least USD $5 million by that time. The two companies plan to issue a joint public announcement upon the execution of the definitive agreement and will coordinate a co-branded PR campaign to spotlight Toggle3D.ai’s new strategic direction and business roadmap under TQG’s leadership. #nextech3d.al #otcqx #nexcf #cse #ntar #EvanGappelberg #ARway #AugmentedReality #SpatialMapping #IndoorNavigation #MapDynamics #EventTech #TradeShowSolutions #TechStocks #ARRevenueGrowth #3DTechnology #ProactiveInvestors #toggle3d TQGtechnologies

Followers	44
Posts	4,312
Boards Moderated	0
Alias Born	03/22/2014

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

Gcasa

Join the InvestorsHub Community

Join the InvestorsHub Community

Boards Moderated

General Topic Boards

Stock Specific Boards

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

Gcasa

Join the InvestorsHub Community

Join the InvestorsHub Community

Boards Moderated

General Topic Boards

Stock Specific Boards

Go Ad-Free